-
EP0760666
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP0760666
| EP0760666 - USE OF OLIGONUCLEOTIDE PHOSPHOROTHIOATE FOR DEPLETING COMPLEMENT AND FOR REDUCING BLOOD PRESSURE [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 06.02.1998 Database last updated on 12.10.2024 | Most recent event Tooltip | 06.02.1998 | Withdrawal of application | published on 25.03.1998 [1998/13] | Applicant(s) | For all designated states HYBRIDON, Inc. One Innovation Drive Massachusetts Biotechnology Research Park Worcester Massachusetts 01605 / US | [N/P] |
| Former [1997/11] | For all designated states HYBRIDON, Inc. One Innovation Drive Massachusetts Biotechnology Research Park Worcester, Massachusetts 01605 / US | Inventor(s) | 01 /
GALBRAITH, Wayne, M. 918 Cornell Street Fredericksburg, VA 22401 / US | 02 /
AGRAWAL, Sudhir 61 Lamplighter Drive Shrewsbury, MA 01545 / US | [1997/11] | Representative(s) | Vossius, Volker, et al ZSP Patentanwälte PartG mbB Radlkoferstrasse 2 81373 München / DE | [N/P] |
| Former [1997/11] | Vossius, Volker, Dr., et al Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Holbeinstrasse 5 81679 München / DE | Application number, filing date | 95920471.0 | 19.05.1995 | [1997/11] | WO1995US06161 | Priority number, date | US19940250853 | 27.05.1994 Original published format: US 250853 | [1997/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO9532719 | Date: | 07.12.1995 | Language: | EN | [1995/52] | Type: | A1 Application with search report | No.: | EP0760666 | Date: | 12.03.1997 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.12.1995 takes the place of the publication of the European patent application. | [1997/11] | Search report(s) | International search report - published on: | EP | 07.12.1995 | Classification | IPC: | A61K31/70 | [1997/11] | CPC: |
A61K31/70 (EP);
A61P37/06 (EP);
A61P9/12 (EP)
| Designated contracting states | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1997/11] | Title | German: | VERWENDUNG EINES OLIGONUKLEOTID-PHOSPHOROTIOATES ZUR KOMPLEMENTDEPLETION UND ZUR SENKUNG DES BLUTDRUCKS | [1997/11] | English: | USE OF OLIGONUCLEOTIDE PHOSPHOROTHIOATE FOR DEPLETING COMPLEMENT AND FOR REDUCING BLOOD PRESSURE | [1997/11] | French: | UTILISATION DE PHOSPHOROTHIOATE OLIGONUCLEOTIDIQUE POUR LA DEPLETION DU COMPLEMENT ET LA REDUCTION DE LA PRESSION SANGUINE | [1997/11] | Entry into regional phase | 26.11.1996 | National basic fee paid | 26.11.1996 | Designation fee(s) paid | 26.11.1996 | Examination fee paid | Examination procedure | deleted | Decision about request for accelerated examination - accepted: No | 05.12.1995 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 26.11.1996 | Examination requested [1997/11] | 26.11.1996 | Request for accelerated examination filed | 20.01.1998 | Application withdrawn by applicant [1998/13] | Fees paid | Renewal fee | 07.05.1997 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] - "Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin", REGUL.PEPT., vol. 49, pages 167 - 74 [X] 1-13 * see page 167, summary * * page 170, column R, line 3 - page 171, column R, line 2 * * page 172, column L, line 16 - line 18 * | [XP] - "Antisense inhibition of hypertension in the spontaneously hypertensive rat", HYPERTENSION, vol. 25, no. 3, pages 314 - 9 [XP] 1-13 * see page 314, summary * * page 315, column L, paragraph 1 * * page 318, column L, line 35 - line 38 * | [XP] - "Complement activation and hemostatic changes following intravenous administration of phosphorothioate oligonucleotides in the mokey", ANTISENSE RES.DEV.(FALL 1994), vol. 4, no. 3, pages 201 - 6 [XP] 27-39 * page 206, column L, line 15 - line 32 * | [Y] - "Antisense Nonmuscle Myosin Heavy Chain and c-myb Oligonucleotides Suppress Smooth Muscle Cell Proliferation In Vitro", CIRC.RES., vol. 70, no. 4, pages 835 - 43 [Y] 1-39 * page 835, column L, line 15 - line 20 * * see page 843, reference no. 9; page 836, column L, paragraph 3 - column R, paragraph 1 * * page 837, column R, line 14 - line 18 * * page 842, column L, line 28 - line 40 * | [Y] - "Antisense Oligonucleotides decrease expression of human CD46, a regulator of complement", TRANSPL.PROC., vol. 25, no. 5, pages 2922 - 23 [Y] 1-39 * page 2922 * |